HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

NP 40208

inhibits type I TGF-beta receptor

Also Known As:

NP-40208; NP40208

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Pteridines: 147
      - NP 40208: 1

Experts

1.	Chancey, Amanda L: 1 article (01/2008)
2.	Divakaran, Vijay G: 1 article (01/2008)
3.	Mann, Douglas L: 1 article (01/2008)
4.	Sakata, Yasushi: 1 article (01/2008)
5.	Sekiguchi, Kenichi: 1 article (01/2008)
6.	Sivasubramanian, Natarajan: 1 article (01/2008)

Related Diseases

1.	Fibrosis (Cirrhosis) 01/01/2008 - "In order to determine whether TGF-beta-mediated signaling was responsible for the myocardial fibrosis observed in the MHCsTNF mice, we treated MHCsTNF and littermate control mice from 4 to 12 weeks of age with a novel orally available TGF-beta receptor antagonist (NP-40208). "
2.	Body Weight (Weight, Body) 01/01/2008 - "Treatment with NP-40208 resulted in a significant (P < 0.05) 65% decrease in nuclear translocation of Smad 2/3, a significant (P < 0.05), decrease in the heart-weight to body-weight ratio from 6.5 to 5.7, a approximately 37% decrease in fibrillar collagen content (P < 0.01) and a significant (P < 0.05) decrease in the LV chamber stiffness by approximately 25% in the MHCsTNF mice when compared to diluent-treated controls. "

Related Drugs and Biologics

1.	Fibrillar Collagens
2.	Transforming Growth Factor beta Receptors (TGF beta Receptors)
3.	Transforming Growth Factor beta (TGF-beta)